Given the insufficient capacity of 18F-FDG PET to assess tumor response during the early stages of immunotherapy, we sought to develop radiotracers targeting granzyme B that were secreted by effector CD8+ cytotoxic T lymphocytes (CTLs) during immunotherapy (Figure 2A). Here, GZMB is linked to neoplasm.